[EN] 5,6,7,8-TETRAHYDRO[1,2,4]TRIAZOLO[4,3-a]PYRAZINE DERIVATIVES AS P2X7 MODULATORS<br/>[FR] DÉRIVÉS DE 5,6,7,8-TÉTRAHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZINE COMME MODULATEURS DE P2X7
申请人:GLAXO GROUP LTD
公开号:WO2010125102A1
公开(公告)日:2010-11-04
The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof wherein A is hydrogen, C1-4alkyl, C3-6cycloalkyl, C1-3alkoxy, C1-3alkoxy C1-4alkyl, C1-2fluoroalkyl, halogen, NR6 R7, optionally substituted heteroaryl (Het), or optionally substituted phenyl, and R1, R2, R3, R4, R5, R6 and R7 are as defined in the description. The compounds or salts are thought to modulate P2X7 receptor function and to be capable of antagonizing the effects of ATP at the P2X7 receptor. The invention also provides the use of the compound or salt in the treatment or prophylaxis of, for example, inflammatory pain, neuropathic pain, visceral pain, rheumatoid arthritis, osteoarthritis or neurodegenerative disorders.
Triazolopiperazine-amides as dipeptidyl peptidase IV inhibitors: Close analogs of JANUVIA™ (sitagliptin phosphate)
作者:Dooseop Kim、Jennifer E. Kowalchick、Scott D. Edmondson、Anthony Mastracchio、Jinyou Xu、George J. Eiermann、Barbara Leiting、Joseph K. Wu、KellyAnn D. Pryor、Reshma A. Patel、Huaibing He、Kathryn A. Lyons、Nancy A. Thornberry、Ann E. Weber
DOI:10.1016/j.bmcl.2007.03.098
日期:2007.6
A series of beta-aminoamides bearing triazolopiperazines has been prepared and evaluated as potent, selective, orally active dipeptidylpeptidaseIV (DPP-4) inhibitors. Efforts at optimization of the beta-aminoamide series, which ultimately led to the discovery of JANUVIA (sitagliptin phosphate, compound 1), are described.
5,6,7,8-TETRAHYDRO[1,2,4]TRIAZOLO[4,3-a]PYRAZINE DERIVATIVES AS P2X7 MODULATORS
申请人:Dean David Kenneth
公开号:US20120157436A1
公开(公告)日:2012-06-21
The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof:
wherein A is hydrogen, C
1-4
alkyl, C
3-6
cycloalkyl, C
1-3
alkoxy, C
1-3
alkoxy C
1-4
alkyl, C
1-2
-fluoroalkyl, halogen, NR
6
R
7
, optionally substituted heteroaryl, or optionally substituted phenyl, and R
1
, R
2
, R
3
, R
4
, R
5
, R
6
and R
7
are as defined in the description.
The compounds or salts are thought to modulate P2X7 receptor function and to be capable of antagonizing the effects of ATP at the P2X7 receptor. The invention also provides the use of the compound or salt in the treatment or prophylaxis of, for example, inflammatory pain, neuropathic pain, visceral pain, rheumatoid arthritis, osteoarthritis or neurodegenerative disorders.